Nventa Develops Proprietary Vaccine Adjuvant
SAN DIEGO, June 18 /PRNewswire/ --
- Potent Adjuvant is a Toll-Like Receptor 3 (TLR3) Agonist
Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the company has developed a…